Novo Nordisk A/S (NOV.DE)
EUR 103.14
(-0.33%)
EUR 103.14
(-0.33%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.14 Billion DKK | -23.08% |
| 2022 | 2.78 Billion DKK | 114.58% |
| 2021 | 1.29 Billion DKK | -55.19% |
| 2020 | 2.89 Billion DKK | 0.0% |
| 2019 | - EUR | 0.0% |
| 2018 | - EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| 2016 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 51.6 Billion DKK | 207.85% |
| 2024 Q1 | 2.24 Billion DKK | 4.93% |
| 2023 FY | 2.14 Billion DKK | -23.08% |
| 2023 Q2 | 2.6 Billion DKK | -20.01% |
| 2023 Q4 | 2.14 Billion DKK | -19.61% |
| 2023 Q1 | 3.25 Billion DKK | 16.71% |
| 2023 Q3 | 2.66 Billion DKK | 2.48% |
| 2022 Q4 | 2.78 Billion DKK | -13.92% |
| 2022 Q2 | 3.24 Billion EUR | 0.12% |
| 2022 Q3 | 3.23 Billion EUR | -0.16% |
| 2022 Q1 | 3.23 Billion EUR | 85.78% |
| 2021 Q4 | 1.74 Billion EUR | 4.54% |
| 2021 Q3 | 1.66 Billion EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| BioNTech SE | 191 Million EUR | -1021.753% |
| CureVac N.V. | 36.81 Million EUR | -5719.136% |
| Biotest Aktiengesellschaft | 377.3 Million EUR | -467.863% |
| Biotest Aktiengesellschaft | 377.3 Million EUR | -467.863% |
| BRAIN Biotech AG | 25.19 Million EUR | -8404.535% |
| Formycon AG | 7.81 Million EUR | -27315.836% |
| Heidelberg Pharma AG | 70.4 Thousand EUR | -3042988.845% |
| Medigene AG | 2.03 Million EUR | -105133.181% |